Injection site reaction after Moxidectin (ProHeart 6) in dogs

The FDA has received 1,295 reports of injection site reaction in dogs after Moxidectin. That is 2.6% of all reports for this medicine, compared with 1.0% across reports for all dog medicines, so it is reported unusually often with this medicine.

1,295Reports
35%Marked serious
14%Recovered
3.0%Died or euthanised
6 daysTypical onset
SponsoredWorried about your pet? Ask a veterinarian online, 24/7

How soon it started

Same day
245 27%
1–2 days
110 12%
3–7 days
148 17%
1–4 weeks
228 26%
Over a month
162 18%

How the animals did

Recovered
179 14%
Still unwell when reported
684 53%
Died
21 1.6%
Euthanised
18 1.4%
Not known
393 30%

Problems reported at the same time

393 30%
175 14%
105 8.1%
98 7.6%
82 6.3%
71 5.5%

Age of the animals

Under 1 year
57
1–3 years
412
4–7 years
486
8–11 years
236
12+ years
68

About this medicine

Moxidectin prevents heartworm disease (monthly topical, or a 6- or 12-month injection for dogs).

Products with this ingredient include ProHeart 6, ProHeart 12. The FDA hides brand names in its public data, so these reports cover every product with the same active ingredients.

Some herding breeds (for example Collies) carry the MDR1 gene variant and can be more sensitive to this drug class at high doses.

Questions owners ask

Can Moxidectin cause injection site reaction in dogs?
1,295 reports link the two, but a report alone does not prove the medicine was the cause: other illnesses, other medicines or coincidence can be involved. Your vet can judge it for your animal.
How soon after a dose was it reported?
In half of the reports with dates, it started within 6 days of the first dose.
What should I do?
Don't give another dose until you've spoken to your vet, and keep the packaging so you can tell them the product and dose. Your vet can also report it to the FDA (or you can, through the manufacturer or FDA form 1932a).

Injection site reaction with similar medicines

All reported side effects of Moxidectin in dogs · Medicines most reported with injection site reaction